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Objective
To determine how best to use magnetic resonance imaging
(MRI) and targeted MRI/ultrasonography fusion biopsy for
early detection of prostate cancer (PCa) in men with elevated
prostate-specific antigen (PSA) concentrations and whether it
can be cost-effective.
Methods
A Markov model of PCa onset and progression was
developed to estimate the health and economic consequences
of PCa screening with MRI. Patients underwent PSA
screening from ages 55 to 69 years. Patients with elevated
PSA concentrations (>4 ng/mL) underwent MRI, followed by
targeted fusion or combined (standard + targeted fusion)
biopsy on positive MRI, and standard or no biopsy on
negative MRI. Prostate Imaging Reporting and Data System
(PI-RADS) score on MRI was used to determine biopsy
decisions. Deaths averted, quality-adjusted life-years (QALYs),
cost and incremental cost-effectiveness ratio (ICER) were
estimated for each strategy.
Results
With a negative MRI, standard biopsy was more expensive
and had lower QALYs than performing no biopsy. The
optimum screening strategy (ICER $23 483/QALY)
recommended combined biopsy for patients with PI-RADS
score ≥3 and no biopsy for patients with PI-RADS score <3,
and reduced the number of screening biopsies by 15%.
Threshold analysis suggests MRI continues to be cost-effective
when the sensitivity and specificity of MRI and combined
biopsy are simultaneously reduced by 19 percentage points.
Conclusions
Our analysis suggests MRI followed by targeted MRI/
ultrasonography fusion biopsy can be a cost-effective
approach to the early detection of PCa.
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Introduction
Concerns about the poor sensitivity and specificity of the PSA
test have led to recommendations to discontinue prostate
cancer (PCa) screening in the USA [1]. A key factor leading
to this recommendation is that PSA does not distinguish
between likely indolent and potentially lethal PCa [2]. As a
result, many men who undergo PSA screening receive
biopsies, with negative results, which are associated with pain,
anxiety and the potential for infection [3]. Eliminating
screening spares patients from unnecessary biopsies; however,
it also results in late detection of intermediate- and high-
grade cancers, potentially leading to poor outcomes for these
patients [4].
Recently, MRI has been proposed as a way to achieve early
detection of high-grade cancer in a minimally invasive way.
This would potentially reduce overtreatment by preferentially
detecting intermediate- and high-grade cancers [5–8];
however, MRI is costly and there is limited evidence for its
effectiveness as an intermediate test in patients being screened
for PCa. Moreover, there are multiple ways to use MRI in a
screening setting, and it is not clear which is best. For
example, if an MRI does not detect lesions suspicious for
PCa, either no biopsy or a standard biopsy (which randomly
samples cores of tissue from the entire prostate gland) can be
performed. If an MRI detects suspicious lesions, a targeted
MRI/ultrasonography fusion biopsy (i.e. targeted fusion
biopsy) can be performed in which the images from MRI are
used with real-time ultrasonography to sample cores of tissue
directly from suspicious lesions; alternatively, a combined
approach can be used in which both standard and targeted
fusion biopsies are performed during a single biopsy session.
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As there are multiple ways to implement MRI in a screening
setting, the optimal clinical pathway is unknown.
We used a Markov model to evaluate the cost-effectiveness of
MRI in a screening setting. We used the model to predict
outcomes based on simulation for five screening strategies
and report the results on the basis of 1 000 men. The
frequency of screening for each strategy was based on the
AUA guideline for PSA screening. The first strategy included
the standard biopsy for men with elevated PSA
concentrations (>4 ng/mL) [9]. The other four strategies
involved performing MRI on men with elevated PSA
concentrations, and the results were used to decide whether
the men should be referred for no biopsy, standard biopsy,
targeted fusion biopsy, or combined (standard + targeted
fusion) biopsy. We estimated the number of deaths averted,
quality-adjusted life-years (QALYs) gained, and the total cost
for each strategy. Additionally, we estimated the incremental
cost-effectiveness ratios (ICERs).
Methods
We extended a recently validated partially observable Markov
model to estimate outcomes for MRI-based screening
strategies [10]. The extended Markov model included five
pretreatment states that are not directly observable, including
no PCa, organ-confined PCa based on Gleason score (<7, 7,
>7), and extraprostatic or lymph node-positive cancer. This
established model simulates the onset and progression of PCa
from age 40 years until end-of-life, and has been validated in
Barnett et al. [10]. We incorporated the five biopsy strategies
and updated the annual metastasis rate to calibrate our model
based on estimates from the literature [11]. Our revised
model estimates for expected life-years gained and QALYs
gained from PSA screening have external validity relative to
another recent cost-effectiveness study of PSA screening [12].
For each strategy, we used 30 000 000 samples of biopsy-
na€ıve men who were screened every 2 years from age 55 to
69 years according to the AUA guideline. In strategy 1, a
standard biopsy was recommended for elevated PSA
concentration (>4 ng/mL). The decision rule diagram for
strategies 2–5 is shown in Fig. 1. Each strategy from 2 to 5
recommended MRI for elevated PSA concentration, while
actions based on the MRI results depended on the strategy as
defined in Table 1. Our model focused on initial biopsy
decisions; thus, the screening strategy terminates after the
patient receives an initial biopsy or two negative MRI results.
However, the patient continues to make state transitions in
the absence of screening until all-other-cause mortality or
clinical detection of and subsequent mortality from PCa.
The model comprised discrete health states based on Gleason
score, which are not directly observable but can be inferred
from PSA and MRI subject to published estimates of sensitivity
and specificity. In our model, we considered clinically
significant disease to be any Gleason score ≥7. For standard
biopsy, the results were randomly sampled as either positive or
negative for any PCa, assuming a sensitivity of 80.0% [13]. If
the biopsy result was positive, the probability that the biopsy
provides an incorrect grading at diagnosis was based on data
reported by Epstein et al. [14]. For targeted fusion and
combined biopsy, we used the values of sensitivity and
specificity for high-grade cancer (high-volume Gleason 3 + 4 or
≥ Gleason 4 + 3) reported in Siddiqui et al. [5] of 77.0% and
68.0%, respectively, for targeted fusion biopsy, and 85.0% and
49.0%, respectively, for combined biopsy. Based on Medicare
infection rates reported in Loeb et al. [15], 1.1% of biopsies
performed led to hospitalization for post-biopsy infection [3].
In addition to detection of PCa through routine screening,
the model incorporated the clinical detection of symptomatic
PCa. For each patient, we randomly sampled a lead time
from an elevated PSA measurement of ≥3 ng/mL to clinical
diagnosis of PCa from a distribution developed by Savage
et al. [16]. If a patient had PCa and a PSA score ≥3 ng/mL
for their lead time and had not yet been diagnosed with PCa
in the model, it was assumed the patient was clinically
detected as a result of symptoms.
Treatment
Patients with PSA concentration >20 ng/mL or a Gleason
score ≥8 received a bone scan and a CT scan for staging
[17,18]. Patients with a biopsy result of Gleason score ≥7
underwent radical prostatectomy. Based on practice patterns
reported in Liu et al. [19], we assumed that 48.5% of patients
diagnosed with Gleason score 6 PCa underwent active
surveillance, while the rest underwent radical prostatectomy.
If a patient was clinically detected to have PCa after age
80 years, we assumed they received watchful waiting.
Patients on active surveillance received an annual PSA test
and a biopsy every 2 years and continued to progress through












Fig. 1 Decision rule diagram for screening strategies 2–5. All of the
decision rules were compared to no screening and the case of standard
biopsy for PSA greater than 4 ng/mL.
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progression in Gleason score, the patient received radical
prostatectomy. For patients with no indication of progression
within 10 years, survival was consistent with survival for men
with untreated PCa [10]. Patients treated via radical
prostatectomy had survival consistent with a treated
population [20], with the potential for progression to
metastatic PCa and PCa mortality. Other-cause mortality was
based on estimates from Centers for Disease Control and
Prevention life tables [21].
PSA and MRI Sensitivity and Specificity
A published statistical model from the PCa prevention trial
was used to sample age-dependent and cancer onset-
dependent PSA scores [22]. The outcome of MRI was based
on Prostate Imaging Reporting and Data System (PI-RADS)
scores, between 1 and 5, with an increasing score indicating
an increasing likelihood of the presence of clinically
significant cancer [23]. We considered two PI-RADS
thresholds to trigger biopsy: 3 and 4. A PI-RADS threshold of
≥3 had a sensitivity and specificity to clinically significant
PCa (i.e. cancer core involvement of ≥6 mm or the presence
of any Gleason pattern 4) of 96.5% (95% CI: 86.8–99.4) and
59.7% (95% CI: 51.2–67.7), respectively, and a PI-RADS
threshold of ≥4 had sensitivity and specificity values of 78.9%
(95% CI: 65.8–88.2) and 78.9% (95% CI: 69.9–84.1),
respectively [24].
Costs and Quality of Life
We estimated the difference in costs and QALYs for each
combination of the five screening strategies and the two PI-
RADS score thresholds. Cost and QALY estimates with their
sources are shown in Table 2 and our assumptions were
similar to those of previous studies [25–27]. The post-
recovery period for radical prostatectomy was assumed to last
9 years [27]. Li et al. [28] reported the disutility for
Table 1 Definitions of five screening strategies.
Screening
strategy
PSA > 4 ng/mL Positive MRI Negative MRI
1 Standard biopsy – –
2 MRI Targeted fusion biopsy Standard biopsy
3 MRI Targeted fusion biopsy No biopsy
4 MRI Combined biopsy Standard biopsy
5 MRI Combined biopsy No biopsy
Table 2 Costs considered in our cost-effectiveness analysis and annual disutilities for health states.
Intervention Unit costs in $ Source
PSA screening 33.86 Medicare data
MRI 964.21 Medicare data
Standard prostate biopsy* 2 953.67 Medicare data
Targeted fusion prostate biopsy † 3 018.35 Medicare data
Combined prostate biopsy † 3 018.35 Medicare data
Post-biopsy infection-related hospitalization 6 361.31 Adibi et al. [44]
Gonzalez et al. [3]
Staging 1 059.28 Medicare data
Active surveillance–standard biopsy (per year)‡ 1 642.58 Medicare data
Active surveillance–targeted biopsy (per year) ‡ 1 674.92 Medicare data
Active surveillance–combined biopsy (per year) ‡ 1 674.92 Medicare data
Radical prostatectomy 15 752.37 Aizer et al. [25]
Distant-stage initial treatment 17 831.29 Roth et al. [26]
Distant-stage management (per year) 2 500.65 Roth et al. [26]
Other cause of death 5 975.15 Mariotto et al. [45]
Prostate cancer death (age <65 years) 103 884.24 Mariotto et al. [45]
Prostate cancer death (age ≥65 years) 69 256.16 Mariotto et al. [45]
Health state Annual disutility (range) Source
PSA screening 0.00019 (0.0–0.00019) Heijnsdijk et al. [27]
MRI 0.00077 (0.00038–0.0012) Grann et al. [29]
Heijnsdijk et al. [27]
Biopsy 0.00577 (0.00346–0.0075) Heijnsdijk et al. [27]
Post-biopsy infection 0.0161 (0.00969–0.0291) Li et al. [28]
Heijnsdijk et al. [27]
Diagnosis 0.0167 (0.0125–0.0208) Heijnsdijk et al. [27]
Radical prostatectomy 0.247 (0.0917–0.323) Heijnsdijk et al. [27]
Post-radical prostatectomy recovery 0.05 (0.0–0.07) Heijnsdijk et al. [27]
Active surveillance 0.03 (0.0–0.15) Heijnsdijk et al. [27]
Palliative therapy 0.4 (0.14–0.76) Heijnsdijk et al. [27]
Terminal illness 0.3 (0.3–0.38) Heijnsdijk et al. [27]
Costs from the literature have been updated to 2016 US dollars based on inflation. *Includes professional, technical, and facility fees, pathology costs, and office visit. †Includes
professional, technical, and facility fees, pathology costs, office visit, and three-dimensional reconstruction. ‡Assumed to include an annual office visit, annual PSA test, and a biopsy
every 2 years.
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hospitalization attributable to post-biopsy infection to be 0.28,
which we assumed lasted for 3 weeks [27]. Grann et al. [29]
reported the disutility for MRI as 0.04, which we assumed
lasted for 1 week [27].
Cost-Effectiveness
Future costs and QALYs were discounted to net present value
using an annual discount rate of 3% [30]. We identified the
efficient strategies by removing dominated strategies (i.e.
strategies that are more expensive and less effective than
another strategy), as well as strategies ruled out by extended
dominance (i.e. strategies that have higher ICERs than a more
effective strategy) [31]. The ICERs of the efficient policies
were calculated as the incremental costs divided by the
incremental health gains compared with the next most
effective strategy. If the ICER was under $100 000/QALY, the
screening strategy was considered cost-effective [32].
Sensitivity Analysis
To evaluate the robustness of our results, we performed one-
way sensitivity analysis on the net costs per QALY gained
relative to no screening for the optimal screening strategy.
Ranges of the QALY disutilities appear in Table 2. Cost
estimates and other-cause mortality rates [21] were varied by
20%. The sensitivity and specificity of PI-RADS threshold 3
were varied using the 95% CIs reported in Grey et al. [24].
The annual metastasis rate for patients with undiagnosed PCa
was varied within the 95% CI reported in Johansson et al.
[11]. Finally, we varied the annual PCa incidence rate within
the 95% CI reported in Haas et al. [13]. Threshold analysis
was also performed on the sensitivity and specificity of MRI
and combined biopsy under the optimal strategy. Base-case
values of the sensitivity and specificity of MRI were 96.5%
and 59.7%, respectively, and base-case values of the sensitivity
and specificity of combined biopsy were 85.0% and 49.0%,
respectively. During threshold analysis, we simultaneously
reduced the sensitivity and specificity of MRI and combined




Table 3 shows the deaths averted, life-years and QALYs gained,
and number of screening biopsies for each screening strategy.
The largest 95% CI for QALY and cost per patient reflecting
Monte Carlo statistical error was <1% of the corresponding
sample mean point estimate. Strategy 5 with a PI-RADS
threshold of 3 maximized expected QALYs and number of PCa
deaths averted. For every strategy, a PI-RADS threshold of 3
gained more QALYs than a PI-RADS threshold of 4. This
difference was statistically significant for strategies 3–5.
Additionally, performing a combined biopsy after positive MRI
(strategies 4 and 5) resulted in additional QALY gains compared
to performing a targeted fusion biopsy alone (strategies 2 and
3), and these differences were statistically significant.
Figure 2 shows the discounted incremental effectiveness in
QALYs vs the discounted incremental cost for each strategy
relative to no screening. Dominated strategies were
simultaneously more expensive and less effective than at least
one other strategy. Interestingly, all four schemas that
performed a standard biopsy after a negative MRI (strategies 2
and 4, with PI-RADS thresholds of 3 or 4) were dominated by
strategies that performed no biopsy after negative MRI
(strategies 3 and 5). The efficient strategies were strategy 1,
strategy 5 with PI-RADS threshold of 4 and with an ICER of
$14 031/QALY, and strategy 5 with PI-RADS threshold of 3
and with an ICER of $23 483/QALY. Thus, we found strategy
5 (i.e. MRI if PSA >4 ng/mL, combined biopsy if MRI-
positive, no biopsy if MRI-negative) with a PI-RADS threshold
of 3 to be optimal under a willingness-to-pay threshold of
$100 000/QALY. This strategy performed 15% fewer screening
biopsies than the strategy that uses PSA alone (strategy 1).
Table 3 Predicted effects for various screening strategies per 1 000 men. Screening strategies are defined in Table 1.









Strategy 1 4.7 58.7 47.8 (47.2–48.3) 151
Strategy 2, PI-RADS ≥3 5.2 64.1 53.0 (52.4–53.5) 151
Strategy 2, PI-RADS ≥4 5.1 63.0 51.9 (51.3–52.5) 151
Strategy 3, PI-RADS ≥3 5.2 64.3 53.9 (53.3–54.5) 128
Strategy 3, PI-RADS ≥4 4.9 60.3 50.9 (50.3–51.4) 107
Strategy 4, PI-RADS ≥3 5.8 71.4 59.2 (58.6–59.8) 151
Strategy 4, PI-RADS ≥4 5.5 68.7 56.8 (56.2–57.5) 151
Strategy 5, PI-RADS ≥3 5.9 72.6 60.7 (60.1–61.3) 128
Strategy 5, PI-RADS ≥4 5.5 67.8 57.2 (56.6–57.8) 107
Effects are shown without discount. In 2016 US dollars. PCa, prostate cancer; PI-RADS, Prostate Imaging Reporting and Data System; QALY, quality-adjusted life-year. *Compared
with no screening.
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Sensitivity Analysis
Figure 3 shows the one-way sensitivity analysis on the net
costs per QALY gained relative to no screening for strategy
5 with a PI-RADS threshold of 3. We performed one-way
sensitivity analysis on all model variables; Fig. 3 shows the
variables that changed the net costs per QALY gained by at
least $5 000/QALY when using the low and high values.
The three model variables that had the greatest impact were:
(i) the metastasis rate for undiagnosed PCa; (ii) the annual
QALY disutility for the 9-year post-radical prostatectomy
recovery period; and (iii) the annual QALY disutility for
living with metastasis. In the sensitivity analysis, the only
scenario that has a cost per QALY gained relative to no
screening over $100 000/QALY is the case with a
substantially lower risk of developing metastases compared
to the base case, suggesting that our results are robust for
most patients and cost-effective under a willingness-to-pay
threshold of $100 000/QALY. Threshold analysis showed
that strategy 5 with a PI-RADS threshold of 3 remained
cost-effective under a willingness-to-pay threshold of $100
000/QALY when sensitivity and specificity of MRI and
combined biopsy to high-grade cancer were all
simultaneously reduced by 19 percentage points. In
particular, it was still cost-effective when sensitivity and
specificity of MRI were ≥77.5% and ≥40.7%, respectively,
and sensitivity and specificity of combined biopsy were
≥66.0% and ≥30.0%, respectively.
Discussion
Based on our study, MRI as an intermediate test in the
screening of men for PCa is cost-effective assuming a
willingness-to-pay threshold of $100 000/QALY threshold.
The most efficient strategy was the use of MRI if PSA
concentration was >4 ng/mL, followed by combined
biopsy if MRI was positive and no biopsy if MRI was
negative, using a PI-RADS threshold of 3 to indicate a
positive MRI. These results were robust over a range of
sensitivity analyses and were maintained even if the
sensitivity and specificity of MRI and combined biopsy
were reduced by 19 percentage points. Additionally, this
MRI strategy reduced the number of screening biopsies
by 15% compared with using PSA alone to trigger standard
biopsy.
Although MRI has recently been proposed as an effective
way to achieve early detection of PCa, evidence in support
of the use of MRI for early detection of PCa in biopsy-na€ıve
men is sparse. Ahmed et al. [33] showed that MRI could be
effective from a clinical perspective by reducing primary
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Fig. 2 Incremental health benefits and costs associated with alternative screening strategies relative to no screening. Costs and quality-adjusted
life-years (QALYs) are discounted at a rate of 3%. Each point is labeled with the screening strategy and Prostate Imaging Reporting and Data System
(PI-RADS) score threshold. Screening strategies are defined in Table 1. Lines connecting points representing two efficient screening strategies indicate
the incremental cost-effectiveness ratio.
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not consider the cost-effectiveness. Willis et al. [34]
performed clinical decision analysis and de Rooij et al. [35]
performed cost-effectiveness analysis; however, both studies
assumed a fixed sensitivity and specificity of MRI and
assumed that positive MRI was automatically followed by a
targeted fusion biopsy, while negative MRI automatically
results in no biopsy. Thus, they evaluated one clinical
pathway compared with the standard of care. In the present
study we evaluated strategies that performed targeted fusion
biopsy or combined biopsy on positive MRI, as well as the
option to perform a standard biopsy or no biopsy on
negative MRI. Thus, our study evaluated eight MRI-based
clinical pathways (two PI-RADS thresholds for each of the
four MRI-based strategies) compared with screening with
PSA alone, allowing us to estimate the effects of varying
PI-RADS thresholds and biopsy techniques on the cost-
effectiveness of using MRI for PCa screening. More recently,
Pahwa et al. [36] performed cost-effectiveness of using MRI
in biopsy-na€ıve men; however, this study is a decision tree
that did not consider various PI-RADS scores and did not
account for sequential PSA testing or progression of cancer
over time. Additionally, their study does not incorporate
other-cause mortality, which is an important consideration
when studying a disease like PCa, which can be slow-
growing. Finally, to our knowledge, the present study is the
first to focus on the use of MRI in a screening setting in
combination with PSA and incorporates lifetime costs and
health outcomes, rather than assessing short-term outcomes.
Including long-term costs and health impacts enabled us to
assess the potentially negative impact of detecting low-risk
cancers related to harm from biopsy/biopsies and
overtreatment. Previous studies did not account for the costs
and harms associated with biopsy complications, resulting in
an overestimation of the benefit from screening and an
underestimation of the costs.
Heijnsdijk et al. [12] evaluated the cost-effectiveness of
several PSA screening policies in the absence of MRI, and our
models produced similar expected outcomes for PSA
screening. The net cost per QALY gained reported in the
present study for PSA screening was lower than the results
reported in Heijnsdijk et al. [12] because we included more
costs in our model, including the significant cost of a PCa-
related death. Faria et al. [37] recently published a cost-
effectiveness study based on the Prostate MR Imaging Study
(PROMIS) based in the UK and found that performing
multiparametric MRI followed by up to two targeted TRUS-
guided biopsies was a cost-effective approach to early
detection of PCa, reaching a similar conclusion to that of the
present study.
Using MRI for PCa screening resulted in health benefits for
the patient compared with both no screening and screening
using PSA alone. For example, the screening strategy
whereby men with a PI-RADS score ≥3 were recommended
for combined biopsy (i.e. strategy 5) resulted in 5.9 deaths
from PCa averted, 60.7 QALYs gained, and 72.6 life-years
gained per 1 000 men compared with no screening. For every
screening strategy, a PI-RADS threshold of 3 outperformed a
threshold of 4 in terms of QALYs. Our results also suggest
that performing a combined biopsy after a positive MRI
outperforms performing a targeted fusion biopsy in terms of
QALYs; however, there does not appear to be a benefit to
performing standard biopsy on negative MRI, because it
results in additional costs and disutility to the patient without
added health benefits. This conclusion has been supported in
the literature. For example, Hansen et al. [38] concluded that
biopsies may not be necessary for men with elevated PSA
and non-suspicious MRI because the negative predictive
value for excluding Gleason score ≥7 disease on MRI was
very high. The present study adds additional evidence in
support of this conjecture.
The results are sensitive to the choice of disutility estimates
used to compute QALYs. Because we assumed patients
undergoing definitive treatment would have surgery, the
Metastasis rate for undiagnosed PCa





Transition rate from No PCa to G5<7
Net costs per QALY gained relative to no screening ($/QALY) 
$- $50,000 $100,000 $150,000 
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Fig. 3 Tornado diagram of one-way sensitivity analysis on the net costs per quality-adjusted life-year (QALY) gained of strategy 5 with a Prostate
Imaging Reporting and Data System (PI-RADS) score threshold of 3 relative to no screening. Costs and QALYs are discounted at a rate of 3%. PCa,
prostate cancer; RP, radical prostatectomy; GS, Gleason score.
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results do not necessarily apply to those patients who may
receive radiation treatment. This is because disutility
estimates for radiation treatment are not readily available;
however, other authors have noted the similarity in the
disutility for these alternative treatment options [39].
It is important to note that the cost figures used in the present
study are from the USA and the cost and ICER threshold used
to define willingness to pay will vary depending on the specific
healthcare setting. For example, in the UK the threshold is
typically £20 000–£30 000 per QALY gained [40].
Given the wide variability in the quality of radiology
reporting and interpretation of MRI results, we performed
threshold analysis on the sensitivity and specificity of MRI
and combined biopsy. These analyses found this approach
to be a cost-effective method of early detection even if the
sensitivity and specificity were substantially lower than
estimates reported in the literature, suggesting that our
results may be relevant in a community setting where
sensitivity and specificity may be lower than in specialized
medical centres where most previous MRI studies have
been conducted. Despite these encouraging findings,
minimizing variation in radiologist reporting remains a
critical unmet need [41,42]. The minimum thresholds we
found for sensitivity and specificity of MRI in our
sensitivity analysis were within the range of clinical
possibility. Prospective tracking of outcomes data stratified
by indication and PI-RADS v2 scoring is necessary to
ensure performance within the range of values we studied
can be achieved.
Our model was based on available evidence but there are a
number of noteworthy limitations. One potential limitation
is that there was the potential for bias in the data we used
to estimate MRI results because the population used
included patients with previous negative biopsies in
addition to biopsy-na€ıve patients; however, by using the
estimates based on the larger patient population we were
able to obtain better estimates of sensitivity and specificity.
Our sensitivity analysis further confirms our conclusions
are not sensitive to this assumption. Another possible
limitation is the inconsistent definition of clinically
significant PCa in the literature. For example, Siddiqui
et al. [5] defined clinically significant disease as high-
volume Gleason 3 + 4, or Gleason ≥4 + 3, while Grey
et al. [24] defined it as cancer core involvement ≥6 mm or
the presence of any Gleason pattern 4. In our model, we
considered clinically significant disease to be any Gleason
score ≥7. Additionally, the only curative treatment included
in our model was radical prostatectomy, because it is the
most common curative treatment, and patients undergoing
radiation therapy have similar health outcomes [43]. Our
model uses many different sources of data; however, given
the long-term evaluation period needed for PCa screening,
randomized trials are unlikely to be able to assess long-
term QALYs and costs. We considered multiple ways of
using MRI for early detection, but MRI may also play an
important role in active surveillance. We have not
attempted to incorporate this aspect of MRI into the model
because of the complexity of decisions and evidence related
to the use of MRI for active surveillance. These limitations
notwithstanding, we believe the present study provides
important evidence in support of the use of MRI for early
detection of PCa in biopsy-na€ıve men, both from a health
benefit and cost perspective.
Our results show that incorporating MRI into PCa screening
in biopsy-na€ıve men is cost-effective under a willingness-to-
pay threshold of $100 000/QALY. The strategies that
performed a standard biopsy on negative MRI were more
expensive and less effective than strategies that performed no
biopsy on negative MRI. The screening strategy where men
with PI-RADS score ≥3 were recommended for combined
biopsy, while men with PI-RADS score <3 were
recommended for no biopsy was optimal and cost-effective
with an ICER of $23 483/QALY. Our results were also robust
with respect to sensitivity analysis. MRI appears, therefore, to
be a viable approach for early detection of PCa from a cost-
effectiveness perspective.
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